Dale Pfost

Dale R.
Pfost has founded MicroBiome Therapeutics LLC in 2009.
He held the title of Chief Executive Officer & Director at MicroBiome Therapeutics LLC from 2016 to 2019.
Currently, Dr. Pfost holds the position of Chairman at Biopticon Corp.
He is also the Co-Chairman at AxoSim, Inc. since 2024.
Additionally, he is a Director at Ancilia Biosciences, Inc. since 2021.
Dr. Pfost has held several former positions.
He was the Chairman, President & Chief Executive Officer at Orchid Cellmark, Inc. from 1996 to 2002.
He served as the Chief Executive Officer at Receptor BioLogix, Inc. from 2008 to 2009.
From 2003 to 2007, he held the positions of Chairman, President & Chief Executive Officer at Acuity Pharmaceuticals, Inc. He was the President & Chief Executive Officer at Oxford GlycoSciences Plc from 1988 to 1996.
He also served as the Chairman & Chief Executive Officer at Lodo Therapeutics Corp.
from 2019 to 2021 and at Chemomab Therapeutics Ltd. from 2021 to 2023.
Additionally, he was the Executive Chairman at Vestagen Protective Technologies, Inc. from 2013 to 2017.
He has also held various director positions at Nicoventures Trading Ltd., Aura Biosciences, Inc., Smithkline Beckman Corp, CalEthos, Inc., Bioelectronica Corp., Ancilia Biosciences, Inc., and eXegenics, Inc. He was a General Partner at Advent Venture Partners LLP from 2010 to 2019.
He was also the President of Infinitek Solutions.
Dr. Pfost's education includes a doctorate degree from Brown University, an undergraduate degree from the University of California, Santa Barbara, and an undergraduate degree from the University of California.